Business

Aradigm Corporation has received a 2-year Small Business Initiative Research (SBIR) grant of about $972,000 from the National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Health (NIH) for development of Linhaliq and Lipoquin to treat pulmonary non-tuberculous mycobacteria (NTM) infections, the company said. The grant will support … [Read more...] about Aradigm gets SBIR grant for development of Linhaliq and Lipoquin for NTM

According to Verona Pharma's mid-year update, the company is developing MDI and DPI formulations of its RPL554, an inhaled PDE3/PDE4 inhibitor. Nebulized RPL554 is currently in Phase 2 development, and Verona reported positive results from a Phase 2a trial of RPL554 for the treatment of acute exacerbations in COPD patients in March 2016. The company said that it … [Read more...] about Verona Pharma developing MDI and DPI formulations of RPL554

Innovus Pharmaceuticals says that it has ordered 220,000 units of FlutiCare, an OTC fluticasone propionate nasal spray, in preparation for its US launch in the fourth quarter of 2017. The company says that it will launch a 120 spray version of the product for the treatment of allergic rhinitis. Innovus acquired the FlutiCare brand in 2015 when it acquired Novalere … [Read more...] about Innovus Pharma preparing fo upcoming launch of FlutiCare nasal spray in US

Endo Pharmaceuticals filed suit against Lupin on July 28, 2017 alleging infringement of patents related to Par's Nascobal cyanocobalamin nasal spray. The suit was filed in the United States District Court for the Eastern District of Texas and was assigned to Judge Rodney Gilstrap. The patents cited in the suit include US patents 7,229,636; 7,404,489; 7,879,349; … [Read more...] about Endo files suit against Lupin for infringement of Nascobal nasal spray patents

Milestone Pharmaceuticals has raised $55 million in a Series C financing round led by Novo Holdings A/S, the company said. The company plans to use the money to fund Phase 3 clinical development of etripamil, an intranasal calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT). Earlier this year, Milestone announced positive … [Read more...] about Milestone Pharmaceuticals raises $55 million for development of intranasal etripamil

Dewmar International says that it has filed a provisional patent application titled "Cannabinoid Formulation to Treat Lung Cancer" with the United States Patent and Trademark Office (USPTO). The companies current brands include "Kush Cakes" psychedelic brownies and "Canna Energy" hemp drinks. According to Dewmar, "The invention relates to an inhalation … [Read more...] about Dewmar International files provisional patent application for inhaled cannabinoid lung cancer therapy

Perrigo announced that it has settled Hatch-Waxman litigation brought by Meda Pharmaceuticals and Cipla regarding Dymista azelastine HCl/fluticasone propionate nasal spray. Meda's NDA for Dymista was approved by the FDA for the treatment of allergic rhinitis in 2012. Meda was acquired by Mylan in 2016. Perrigo Executive VP and President, Rx Pharmaceuticals, … [Read more...] about Perrigo settles litigation related to Dymista nasal spray

Sunovion has announced that it has agreed to divest US rights to the Alvesco ciclesonide MDI for the treatment of asthma and the Omnaris and Zetonna ciclesonide nasal sprays for the treatment of allergic rhinitis to Covis Pharma. The company acquired the US rights to the products from Takeda in 2008 and launched Alvesco and Omnaris that same year. Zetonna, an HFA … [Read more...] about Sunovion divests US rights to its ciclesonide aerosol products to Covis Pharma

During a July 11, 2017 meeting between AstraZeneca CEO Pascal Soriot and Australian Prime Minister Malcolm Turnbull, Soriot announced an A$100 million expansion of the company's manufacturing facility in Sydney, which he called "really a center of excellence for us, for the manufacture of inhaler products for the treatment of asthma and COPD." The Sydney facility … [Read more...] about AstraZeneca to invest A$100 million to expand Pulmicort Respules plant in Australia